Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 13/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4896282 | 0.85 | CNR2 (0.47) | CNR2KDM4ENPC1ALOX15TSHR | |
| SCHEMBL4896507 | 0.84 | CNR2 (0.46) | CNR2KDM4ENPC1ALOX15TSHR | |
| SCHEMBL4896789 | 0.83 | CNR2 (0.63) | CNR2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4886685 | 0.82 | HTT (0.51) | CNR2KDM4ENPC1ALOX15TSHR | |
| SCHEMBL4886635 | 0.82 | CNR2 (0.53) | CNR2KDM4ENPC1ALOX15TSHR | |
| SCHEMBL14026125 | 0.81 | CNR2 (0.61) | CNR2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL5708636 | 0.79 | CNR2 (0.51) | CNR2KDM4ENPC1ALOX15TSHR | |
| SCHEMBL4896851 | 0.78 | CNR2 (0.53) | CNR2KDM4ENPC1ALOX15TSHR | |
| Formic Acid SCHEMBL4896050 | 0.78 | CNR2 (0.60) | CNR2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4896457 | 0.76 | CNR2 (0.61) | CNR2KDM4ENPC1ALOX15TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261977-A1 | Pyrimidine Derivatives as Cannabinoid Receptor Modulators | GLAXO GROUP LIMITED (GB) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261977-A1 | Pyrimidine Derivatives as Cannabinoid Receptor Modulators | CNR2, CNR1, P2RY2 | CNR2 1/4885KDM4E 2470/4885NPC1 1587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.